Your browser doesn't support javascript.
loading
Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy.
Winkelmann, Michael; Blumenberg, Viktoria; Rejeski, Kai; Quell, Christina; Bücklein, Veit L; Ingenerf, Maria; Unterrainer, Marcus; Schmidt, Christian; Dekorsy, Franziska J; Bartenstein, Peter; Ricke, Jens; von Bergwelt-Baildon, Michael; Subklewe, Marion; Kunz, Wolfgang G.
Affiliation
  • Winkelmann M; Department of Radiology, University Hospital, LMU Munich, Munich, Germany.
  • Blumenberg V; Laboratory for Translational Cancer Immunology, Gene Center of the LMU Munich, Munich, Germany; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
  • Rejeski K; Laboratory for Translational Cancer Immunology, Gene Center of the LMU Munich, Munich, Germany; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
  • Quell C; Department of Radiology, University Hospital, LMU Munich, Munich, Germany.
  • Bücklein VL; Laboratory for Translational Cancer Immunology, Gene Center of the LMU Munich, Munich, Germany; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
  • Ingenerf M; Department of Radiology, University Hospital, LMU Munich, Munich, Germany.
  • Unterrainer M; Department of Radiology, University Hospital, LMU Munich, Munich, Germany.
  • Schmidt C; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
  • Dekorsy FJ; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
  • Bartenstein P; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany; Comprehensive Cancer Center München-LMU (CCCMLMU), LMU Munich, Munich, Germany.
  • Ricke J; Department of Radiology, University Hospital, LMU Munich, Munich, Germany; Comprehensive Cancer Center München-LMU (CCCMLMU), LMU Munich, Munich, Germany.
  • von Bergwelt-Baildon M; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; Comprehensive Cancer Center München-LMU (CCCMLMU), LMU Munich, Munich, Germany.
  • Subklewe M; Laboratory for Translational Cancer Immunology, Gene Center of the LMU Munich, Munich, Germany; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; Comprehe
  • Kunz WG; Department of Radiology, University Hospital, LMU Munich, Munich, Germany; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany; Comprehensive Cancer Center München-LMU (CCCMLMU), LMU Munich, Munich, Germany. Electronic address: wolfgan
Cytotherapy ; 25(9): 986-992, 2023 09.
Article de En | MEDLINE | ID: mdl-37055322
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Récepteurs chimériques pour l'antigène / Lymphomes / Tumeurs Type d'étude: Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Humans Langue: En Journal: Cytotherapy Sujet du journal: TERAPEUTICA Année: 2023 Type de document: Article Pays d'affiliation: Allemagne Pays de publication: Royaume-Uni
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Récepteurs chimériques pour l'antigène / Lymphomes / Tumeurs Type d'étude: Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Humans Langue: En Journal: Cytotherapy Sujet du journal: TERAPEUTICA Année: 2023 Type de document: Article Pays d'affiliation: Allemagne Pays de publication: Royaume-Uni